Regulus reports Q1 EPS (15c), consensus (26c)

As of March 31, 2025, Regulus (RGLS) had $65.4M in cash, cash equivalents and short-term investments. Expects cash runway to extend into early 2026. “We recently announced that we have entered into an agreement to be acquired by Novartis, whose established global development and commercial capabilities will potentially bring farabursen to patients with ADPKD, who currently have limited treatment options,” said CEO Jay Hagan. “We’ve made important progress with farabursen so far this year, having announced positive results from the completed fourth cohort of patients in March, reporting evidence of a mechanistic dose response based on urinary PC1 and PC2 levels, and results suggesting that kidney volume growth rate was halted after only a relatively short treatment period. We look forward to investigating further as we head towards initiation of the pivotal Phase 3 trial in Q3 of this year.”